169 related articles for article (PubMed ID: 38030599)
1. Arsenic trioxide extends survival of Li-Fraumeni syndrome mimicking mouse.
Li J; Xiao S; Shi F; Song H; Wu J; Zheng D; Chen X; Tan K; Lu M
Cell Death Dis; 2023 Nov; 14(11):783. PubMed ID: 38030599
[TBL] [Abstract][Full Text] [Related]
2. Reducing Fatty Acid Oxidation Improves Cancer-free Survival in a Mouse Model of Li-Fraumeni Syndrome.
Wang PY; Ma J; Li J; Starost MF; Wolfgang MJ; Singh K; Pirooznia M; Kang JG; Hwang PM
Cancer Prev Res (Phila); 2021 Jan; 14(1):31-40. PubMed ID: 32958587
[TBL] [Abstract][Full Text] [Related]
3. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
4. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
[TBL] [Abstract][Full Text] [Related]
5. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
[TBL] [Abstract][Full Text] [Related]
6. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.
Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ
Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
8. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
9. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.
Liu PK; Kraus E; Wu TA; Strong LC; Tainsky MA
Oncogene; 1996 Jun; 12(11):2267-78. PubMed ID: 8649766
[TBL] [Abstract][Full Text] [Related]
10. A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome.
Id Said B; Malkin D
Cancer Genet; 2015; 208(1-2):47-51. PubMed ID: 25683625
[TBL] [Abstract][Full Text] [Related]
11. p53 and hereditary cancer.
Merino D; Malkin D
Subcell Biochem; 2014; 85():1-16. PubMed ID: 25201186
[TBL] [Abstract][Full Text] [Related]
12. Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.
Zhou R; Xu A; Gingold J; Strong LC; Zhao R; Lee DF
Trends Pharmacol Sci; 2017 Oct; 38(10):908-927. PubMed ID: 28818333
[TBL] [Abstract][Full Text] [Related]
13. Unaffected Li-Fraumeni Syndrome Carrier Parent Demonstrates Allele-Specific mRNA Stabilization of Wild-Type
Buzby JS; Williams SA; Nugent DJ
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553570
[TBL] [Abstract][Full Text] [Related]
14. Case Report : Li-Fraumeni Syndrome with Central Nervous System Tumors in Two Siblings.
Fang Z; Su Y; Sun H; Ge M; Qi Z; Hao C; Qian S; Ma X
BMC Pediatr; 2021 Dec; 21(1):588. PubMed ID: 34961499
[TBL] [Abstract][Full Text] [Related]
15. Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome.
Ceyhan-Birsoy O; Selenica P; Chui MH; Jayakumaran G; Ptashkin R; Misyura M; Aypar U; Jairam S; Yang C; Li Y; Mehta N; Kemel Y; Salo-Mullen E; Maio A; Sheehan M; Zehir A; Carlo M; Latham A; Stadler Z; Robson M; Offit K; Ladanyi M; Walsh M; Reis-Filho JS; Mandelker D
J Natl Cancer Inst; 2021 Nov; 113(12):1751-1760. PubMed ID: 34240179
[TBL] [Abstract][Full Text] [Related]
16. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome.
Wu CC; Krahe R; Lozano G; Zhang B; Wilson CD; Jo EJ; Amos CI; Shete S; Strong LC
Hum Genet; 2011 Jun; 129(6):663-73. PubMed ID: 21305319
[TBL] [Abstract][Full Text] [Related]
17. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds.
Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K
Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970
[TBL] [Abstract][Full Text] [Related]
18. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
[TBL] [Abstract][Full Text] [Related]
19. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
Gu J; Kawai H; Wiederschain D; Yuan ZM
Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]